tiprankstipranks
Trending News
More News >
Promising Clinical Data and Strong Safety Profile Lead to Buy Rating for Arcellx Inc’s Anito-cel
PremiumRatingsPromising Clinical Data and Strong Safety Profile Lead to Buy Rating for Arcellx Inc’s Anito-cel
27d ago
Arcellx Announces Positive Phase 2 Study Results
Premium
Company Announcements
Arcellx Announces Positive Phase 2 Study Results
27d ago
Arcellx announces data from iMMagine-1 study of anitocabtagene autoleucel
Premium
The Fly
Arcellx announces data from iMMagine-1 study of anitocabtagene autoleucel
27d ago
Arcellx Inc. Receives Buy Rating: Strong Financial Outlook and Promising Data Catalysts
PremiumRatingsArcellx Inc. Receives Buy Rating: Strong Financial Outlook and Promising Data Catalysts
1M ago
Promising Potential of Arcellx Inc’s Anito-cel Program Drives Buy Rating
Premium
Ratings
Promising Potential of Arcellx Inc’s Anito-cel Program Drives Buy Rating
1M ago
Arcellx’s Promising Trial Results and Strategic Partnerships Justify Buy Rating with $121 Target
Premium
Ratings
Arcellx’s Promising Trial Results and Strategic Partnerships Justify Buy Rating with $121 Target
1M ago
Arcellx Inc: Buy Rating Affirmed on Promising Anito-cel Therapy and Strong Financial Position
PremiumRatingsArcellx Inc: Buy Rating Affirmed on Promising Anito-cel Therapy and Strong Financial Position
3M ago
Arcellx Inc’s Anito-cel Therapy: Promising Clinical Results and Strategic Partnerships Support Buy Rating
Premium
Ratings
Arcellx Inc’s Anito-cel Therapy: Promising Clinical Results and Strategic Partnerships Support Buy Rating
3M ago
Arcellx Inc’s Anito-cel: Promising Performance and Positive Outlook with Buy Rating
Premium
Ratings
Arcellx Inc’s Anito-cel: Promising Performance and Positive Outlook with Buy Rating
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100